In terms of sales, the knee hyaluronic acid injections market size is around USD 2,282.4 million in the year 2025 and might increase further up to USD 3,973.2 million in 2035. For the sales growth CAGR, between the period of 2025 to 2035, it would experience a 5.7%. The sales revenue for the year 2024 was approximately about USD 2,167.2 million for knee hyaluronic acid injections.
One of the widely observed growth drivers behind the knee hyaluronic acid injections market includes the growing incidence of cases of osteoarthritis in knees. The said cases could be contributed by causes such as obesity, sedentary lifestyles, and various repetitive joint injuries, as well as the natural aging process with ongoing degeneration of the joint cartilage.
This is a degenerative disease that leads to chronic pain, stiffness, inflammation, and sever restriction of activities, and impacts the quality of the patient's life to an extreme level. Patients, thus, want active treatments in their lifetime so as not to encounter a sharp degeneration that requires surgical interventions to be undertaken in their lifetime.
The most common non-operative interventions are viscosupplements; Hyaluronic acid injections given inside the knee joint resurface lubrication of its space, and hence reduces and enhances patients' mobility, thereby providing them with some significant symptomatic relief.Global Knee Hyaluronic Acid Injections Industry Outlook
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 2,167.2 million |
| Estimated Size, 2025 | USD 2,282.4 million |
| Projected Size, 2035 | USD 3,973.2 million |
| Value-based CAGR (2025 to 2035) | 5.7% |
This demographic will be one of the significant contributors to market growth, since an aging population around the world will drive expansion. The United Nations projects that over 20% of the population will be older than 60 years in 2050, and approximately 15% will have symptomatic OA, one-third with major disability. This demographic shift translates to approximately 130 million individuals worldwide being expected to be suffering from OA by 2050, with an estimated 40 million having significant disability. Increasingly, older populations are prone to degenerative joint diseases; thus, a greater number of knee hyaluronic acid injections will be required as the most effective way of pain relief.
Moreover, the increasing disability burden due to arthritis is making healthcare systems and pharmaceutical companies increase the speed of developing the drug and commercializing knee hyaluronic acid therapeutics. Surge in awareness of minimally invasive treatment options and the shift towards non-opioid pain management further supports this growth. Rising knee osteoarthritis cases are expected to lead to an increased market for knee hyaluronic acid injections, driven by the urgent need for effective long-term symptom relief and improved quality of life for patients worldwide.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The table below indicates the CAGR the market of knee hyaluronic acid injections globally would record between different semi-annual periods running from 2025 to 2035. Business during H1 from 2024 through 2035 will record a growth of CAGR at 5.9%. It then peaks a bit in H2, where CAGR during the same decade shall have reached 6.3%.
| Particular | Value CAGR |
|---|---|
| H1 | 5.9% (2024-2035) |
| H2 | 6.3% (2024-2035) |
| H1 | 5.7% (2025-2035) |
| H2 | 6.4% (2025-2035) |
In the following term, H1 2025-H2 2035 the CAGR should go down low at 5.7 in the first and pick up fairly high at 6.4% in the second half period. In half of the years H1 The market increased its -20.00 BPS, whereas H2 saw an opposite decline, the market has reduced its figures at 13.00 BPS.
Increasing Demand for Outpatient Treatment Is Driving the Growth for Knee Hyaluronic Acid Injections Market.
The increasing trend towards outpatient care is highly driving the knee hyaluronic acid The injections market is experiencing investment by governments and private healthcare operators in the establishment of ambulatory surgical centers (ASCs) and specialized orthopedic care centers. Healthcare infrastructure upgrades in developed and emerging markets are also making hyaluronic acid injections in the knee more accessible and affordable.
According to the Centers for Medicare and Medicaid Services, trends in hospital revenue illustrate increased reliance on outpatient services, based on expectations that demand for outpatient services among those aged 55 and above will continue growing by 16.9% through 2025, following the projected general population growth of 12.6%. Overall, the outpatient sector is expected to grow at a 9 percent annual rate, more swiftly than the 6 percent a year expected for inpatient care.
Some of the factors that are propelling this trend include the desire for price transparency, which will ensnare patients into looking for cheaper but high-value treatments, and the fast pace of technological advancement, which allows various orthopedic procedures to be done in an outpatient setting. Increased preference by patients for minimally invasive, quicker recovery, and the need for hospitals to incentivize activities that are profitable for them drives this further, thus increasing demand for knee hyaluronic acid injections to join the general embrace of outpatient care.
The Rapid Growth of the Aging and Obese Population Is a Key Factor Driving the Adoption of Knee Hyaluronic Acid Injections as A Standard Treatment for Knee Osteoarthritis (OA).
With an increased number of patients in their elder age group along with being obese, there has been an enhanced requirement for hyaluronic acid injections as a first non-surgical procedure in knee OA. Increasing lifestyle diseases like longer living ages with diet disorders and inactive life cycles lead to massive OA cases worldwide. This situation needs effective treatment; viscosupplementation (injecting hyaluronic acid into the knee) becomes one of the trusted alternatives in treating this for relief in pain and for greater mobility.
The WHO observes that the older population, people aged 60 and above will nearly double; from 12% in 2015 up to 22% by 2050. By 2030, more than one sixth of the total world population is expected to age over 60. Aging thus being the single most cause for OA, increasing demand for these injections is the expected result in this demographic drift.
The condition of obesity further increases the requirement for OA treatments. According to the CDC, the obesity prevalence in adults aged 40-59 was 44.3%, while among adults 60 and older, it was 41.5%. According to studies, obesity has a high association with the following percentage of OA, which is 22.9% in patients of obesity surgery. Global demand to enhance the growth of knee hyaluronic acid injection therapeutics will emerge from an obese population.
The evolution in knee hyaluronic acid (HA) injections is going to result in an enormous market expansion opportunity.
Most prominent manufacturers are investing a lot in the advanced formulation viscosupplementation therapies that promise more efficacy and duration of treatment for mild to moderate knee osteoarthritis. Improved formulations, along with combinations with anti-inflammatory agents, produce greater pain relief and improved function in the involved joint.
The growth in treatment pipeline related to osteoarthritis, coupled with branching out in newer technology and continued patent filing, contributes significantly to the market growth. Funding through industry and governments for the scientific research as well as clinical validation of HA-based injections, accelerate regulatory approvals and broaden the base of product adoption. In addition, integration of novel drug delivery mechanisms and biocompatible materials further strengthen the market outlook.
A third example in this category of innovation is Anika Therapeutics' Cingal. This next-generation HA injection uniquely combines HA with a corticosteroid to provide both lubrication and immediate anti-inflammatory effects. It is approved in Europe and Canada and is under clinical trials in the USA for FDA approval, therefore exhibiting the hope for greater market expansion. With further research and development efforts, next-generation HA injections are expected to gain a growing share of the market, and industry players can seize this lucrative opportunity to differentiate their offerings and expand their global footprint.
The Declining Reimbursement Coverage for Knee Hyaluronic Acid (HA) Injections in Key Markets Is a Significant Restraint Impacting Market Growth
The stable reimbursement landscape, to which orthopedic providers have grown accustomed, is increasingly subject to more stringent scrutiny and less generous coverage. Healthcare systems now seek greater efficiency, which reduces the availability of reimbursement for such elective procedures as knee HA injections, thus further limiting patients' access to such care.
The overall effect is that Medicare and Medicaid continue to pay for reimbursement, while private insurance providers hold the final say in coverage. Leading private insurers now use pre-authorization based on medical necessity and appropriateness reviews, making it increasingly likely that insurance companies will deny these procedures. Further, treatment guidelines lately published by the American Academy of Orthopedic Surgeons (AAOS) and the Osteoarthritis Research Society International (OARSI) downplayed the effectiveness of injections of HA for knee OA, further influencing the approach of payers.
Besides the United States, challenges in the area of reimbursement exist in other important markets as well, with health insurers limiting coverage due to the existence of over-the-counter alternatives and online procurement of HA injections. Reduced insurance support and tighter clinical guidelines are likely to influence adoption rates going forward, which would affect the rest of the players in the market since they seek to expand patient access and sustain growth in the market for knee HA injections.
The global knee hyaluronic acid injections industry recorded a CAGR of 2.4% during the historical period between 2020 and 2024. The growth of knee hyaluronic acid injections industry was positive as it reached a value of USD 2,167.2 million in 2024 from USD 1,799.6 million in 2020.
The market knee HA injections has been growing over the years because of increased knee OA prevalence, the elderly population, and the obese segment of the population alongside the demand for non-invasive solutions for pain management. Since its emergence, the market has grown along with the evolution of viscosupplementation with increased usage of single and multi-injection formulae. Reimbursement policies became better, awareness increased, and outpatient and ambulatory surgical centers started multiplying.
The market is likely to continue its expansion with the help of next-generation HA formulations containing molecular advances and combination therapies like corticosteroids, enhancing anti-inflammatory action. The introduction of biocompatible materials and extended-release formulations will lead to better treatment results and adherence from patients. Other factors likely to boost adoption are increasing regulatory approvals, healthcare expenditure, and outpatient care.
Technological innovations will also include innovative drug delivery technologies and regenerative medicine approaches to change the landscape of competition. The increasing need for price transparency, patient demand for minimally invasive treatments, and emerging markets with expanding health infrastructure will ensure future growth, making knee hyaluronic acid injections one of the leading segments in the management of OA.
Tier 1 companies include market leaders with a high share of 47.0% in the global market. Such companies make strategic partnerships and acquisitions as part of their product portfolio extension along with access to new technologies. It also conducts extensive clinical investigations to show how well and safe the products are. Tier 1 also includes such companies as Sanofi S.A., Bioventus LLC, and Ferring B.V.; Zimmer Biomet; Seikagaku Corporation; and Fidia Farmaceutici s.p.a.
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 32.8% market share. They typically pursue partnerships with multispecialty hospitals and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new products to market, additionally targeting specific types medical needs. Also, they emphasize low-cost production processes to provide competitive prices. Major players in tier 2 are Anika Therapeutics, Inc., LG Chem, OrthogenRx, Hanmi Pharm.Co.,Ltd., Chugai Pharmaceutical Co., Ltd. and Haohai Biological Technology.
Lastly, Tier 3 businesses like Meiji Seika Pharma co. ltd, Hangzhou Singclean Medical Products Co., Ltd, TRB Chemedica International SA, Bioiberica S.A.U. and many more. They deal in niche products and serve niche markets, introducing diversity to the sector.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the knee hyaluronic acid injections sales remains dynamic and competitive.
The section below covers the knee hyaluronic acid injections industry analysis for different countries. Research on the market demand as pertains to the key countries of different regions of the world, which includes among others North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle Ease & Africa.
The most significant influence in North America will be exercised by the United States, which is expected to maintain a higher market share through 2035. By that same year, China would strategize to secure a CAGR of 9.3% in South Asia & Pacific.
| Country | Value CAGR (2025 to 2035) |
|---|---|
| United States | 3.7% |
| Germany | 3.9% |
| Japan | 8.8% |
| China | 9.3% |
| India | 8.0% |
| Canada | 6.6% |
| UK | 5.1% |
| South Korea | 5.8% |
The United States market is likely to grow at a CAGR of 3.7% from 2025 to 2035. The market share currently held in the North American market is the highest.
Rising incidences of knee OA in the USA remain one of the prime forces that drive the USA market for HA injections into the knee. According to CDC records, the USA is besieged with the problem wherein more than 32.5 million adults have had to suffer with OA and most are diagnosed as having a knee OA diagnosis. These figures are due to both increased ageing in population groups as well as escalating levels of obesity within a particular group- the main two OA-developing causes.
The increase in the number of elderly and obese people necessitates that many more patients must be provided with effective, non-surgical options to manage their pain and promote joint mobility. HA injections have become one of the most sought-after surgical alternatives for patients who are either ineligible or unwilling to undergo knee replacement surgery. There is adequate demand for HA injections based on wide out-patient accessibility and evolution of the clinical advance, thus making them a preferred choice in the USA market to manage knee OA.
China is likely to have the second-highest market share for knee hyaluronic acid injections in Eastern Europe, which it currently has; the market for this segment in China is going to have a CAGR of 9.3% in the period of 2025-2035.
An established pharmaceutical production sector in China is the hub driver of the market for knee hyaluronic acid (HA) injections. In this context, several domestic companies have been able to manufacture HA injections on a large scale at relatively cheaper prices, including Shandong Freda Biotechnology, Shanghai Jingfeng Pharmaceutical, and Bloomage Biotechnology. These companies have expanded their portfolios with innovative products, improved formulations, and research and development to make treatment more effective.
The strong local manufacturing base will ensure that HA injections are readily available throughout the region and decrease dependency on expensive imports, making treatments more affordable to patients. Additionally, government support for local biopharmaceutical production speeds up market growth. As the need for non-surgical OA treatment increases, the ability of China to produce quality HA injections at competitive prices establishes it as an important supplier on the world scale. This domestic production advantage, with growing healthcare availability, is paving the way for rapid adoption of HA injections in China's urban and rural markets.
The Japanese market is waiting to experience an 8.8% CAGR between 2025 and 2035. It is presently the largest in the South Asia & Pacific region, and this trend is expected to continue during the forecast period.
Japan actually possesses one of the world's most rapidly aging populations, as reported by the World Bank statistics, where over 28% of residents are over 65 years old. Such population trends have demonstrated a marked rise in age-related degenerative diseases, particularly knee OA, which has serious implications for mobility and quality of life. Consequently, with an increasing elderly population, there are increased demands for effective and non-surgical management such as HA injections.
Since the average life span goes beyond 84 years, the only issue is managing chronic joint conditions; an HA injection that reduces pain and improves functions at a site is recommended by many physicians to delay invasive procedures like replacement of the knee. Given that the Japanese healthcare system also favors preventive care and minimally invasive treatments, adoption of HA injections is strongly promoted, hence HA injections should be a part of the strategy in dealing with the increasing OA burden in Japan.
The section contains information about the leading segments in the industry. By product, the three injection knee hyaluronic acid injections segment holds the highest market share of 60.0% in 2025.
| By Product | Value Share (2025) |
|---|---|
| Three Injection Knee Hyaluronic Acid Injections | 60.0% |
Such balance of efficacy, convenience, and cost-effectiveness has given a dominant place in the market to three-injection regimens of knee hyaluronic acid injections. When compared with single injections that, in some cases, have been correlated with lower retention and effectiveness, and five-injection regimens requiring more frequent visits to the clinics, the three-injection protocol gives the middle ground as an optimal choice that offers sustained pain relief and improved joint function without overly burdensome needs on the patients and providers.
Clinically, three-injection treatments have been proven to be more effective for pain relief and improved mobility as preferred by both clinicians and patients. In addition, major markets such as the USA, Japan, and European Countries often prefer three-injection protocols since it has long been supported by excellence in efficacy and cost-effectiveness. As non-surgical osteoarthritis treatment becomes increasingly sought, the three-injection HA treatment continues to gain ground and finds further strength in establishing market supremacy within the knee OA landscape.
| By End User | Value Share (2025) |
|---|---|
| Ambulatory Surgical Centers | 69.9% |
One reason for dominance among end-users within the market is the emergence of Ambulatory Surgical Centers. Being cost-efficient and accessible with the patient-centric model of care, ASCs ensure streamlined administration of HA injections as an outpatient. This in itself reduces hospital visitation and ensures reduced costs incurred by health organizations. Moreover, ASCs now offer the comfort of orthopedic treatment facilities with relatively minimal waiting periods as well as with reduced procedural expenses, significantly changing the patients' preference toward ASCs.
The current trend for outpatient care fueled by health care policies with a focus on value-based treatment helps fortify the position of ASCs in the market. Insurance companies and reimbursement policies are also more favorable toward HA injections due to operational costs being lower compared to hospitals. With advancement in technology improving injection techniques and patient throughput through an ASC, the dominance of ASCs continues to increase as an efficient and readily available alternative for treating knee osteoarthritis with non-surgical pain relief options.
The market players use strategies such as product differentiation by innovative formulations, strategic partnerships with healthcare providers for distribution. Among the key strategic focuses of the companies are their active searches for strategic partners for bolstering the product portfolios and expanding the global market presence.
Recent Industry Developments in Knee Hyaluronic Acid Injections Market:
The global knee hyaluronic acid injections market is projected to witness CAGR of 5.7% between 2025 and 2035.
The global knee hyaluronic acid injections industry stood at USD 2,167.2 million in 2024.
The global market is anticipated to reach USD 3,973.2 million by 2035 end.
India is set to record the highest CAGR of 6.1% in the assessment period.
The key players operating in the global market for knee hyaluronic acid injections include Sanofi S.A., Bioventus LLC, Ferring B.V., Zimmer Biomet, Seikagaku Corporation, Fidia Farmaceutici s.p.a., Anika Therapeutics, Inc, LG Chem, OrthogenRx, Hanmi Pharm.Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Haohai Biological Technology, Meiji Seika Pharma co. ltd and Hangzhou Singclean Medical Products Co.,Ltd.
| Estimated Market Size (2024E) | USD 10,069.3 million |
|---|---|
| Projected Industry Value (2034F) | USD 13,143.3 million |
| Value-based CAGR (2024 to 2034) | 2.70% |
| Market CAGR (2023 to 2033) | 4.3% |
|---|---|
| Market Valuation (2023) | USD 8.5 billion |
| Market Valuation (2033) | USD 13.0 billion |
Explore Biomaterial Insights
View Reports
Knee Hyaluronic Acid Injections Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
